What is the share price of Neuland Laboratories Ltd (NEULANDLAB) today?
The share price of NEULANDLAB as on 19th June 2026 is ₹17345. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Neuland Laboratories Ltd (NEULANDLAB) share?
The past returns of Neuland Laboratories Ltd (NEULANDLAB) share are- Past 1 week: 0.84%
- Past 1 month: 5.47%
- Past 3 months: 43.34%
- Past 6 months: 8.11%
- Past 1 year: 42.04%
- Past 3 years: 491.90%
- Past 5 years: 746.04%
What are the peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB)?
The peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB) include:What is the dividend yield % of Neuland Laboratories Ltd (NEULANDLAB) share?
The current dividend yield of Neuland Laboratories Ltd (NEULANDLAB) is 0.20.What is the market cap of Neuland Laboratories Ltd (NEULANDLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd (NEULANDLAB) is ₹22253.44 Cr as of 19th June 2026.What is the 52 week high and low of Neuland Laboratories Ltd (NEULANDLAB) share?
The 52-week high of Neuland Laboratories Ltd (NEULANDLAB) is ₹19747 and the 52-week low is ₹11500.What is the PE and PB ratio of Neuland Laboratories Ltd (NEULANDLAB) stock?
The P/E (price-to-earnings) ratio of Neuland Laboratories Ltd (NEULANDLAB) is 61.14. The P/B (price-to-book) ratio is 14.59.Which sector does Neuland Laboratories Ltd (NEULANDLAB) belong to?
Neuland Laboratories Ltd (NEULANDLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Neuland Laboratories Ltd (NEULANDLAB) shares?
You can directly buy Neuland Laboratories Ltd (NEULANDLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Neuland Laboratories Ltd
NEULANDLAB Share Price
NSE₹17,345.000.73% (+125.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NEULANDLAB Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NEULANDLAB Performance & Key Metrics
NEULANDLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 61.14 | 14.59 | 0.20% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.31 | 6.16 | 0.55% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
NEULANDLAB Company Profile
Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.
SUNPHARMA
PE Ratio
38.42
38.42
1Y Return
11.57%
11.57%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.30
69.30
1Y Return
40.01%
40.01%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
28.15
28.15
1Y Return
8.91%
8.91%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
21.38
21.38
1Y Return
12.71%
12.71%
Buy Reco %
53.57
53.57
LUPIN
PE Ratio
20.16
20.16
1Y Return
21.73%
21.73%
Buy Reco %
55.56
55.56
NEULANDLAB Sentiment Analysis
NEULANDLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NEULANDLAB Stock Summary · February 2026
Neuland Laboratories reported a robust 11.4% year-over-year increase in total income, driven by its commercial Contract Manufacturing Services, despite facing challenges such as a decline in gross margins and heightened working capital issues. The company is strategically transitioning from low-margin API manufacturing to human health-oriented CDMO services, which necessitates significant investments and a longer-term performance outlook. While high inventory levels raise concerns about efficiency, management remains optimistic about future growth, particularly in peptide manufacturing, where increased interest from innovators is evident. The focus on quality project engagement and a commitment to optimizing cash flow are central to navigating current operational complexities and ensuring sustainable growth in the coming years.
NEULANDLAB Stock Growth Drivers
NEULANDLAB Stock Growth Drivers
8Strategic Growth Initiatives
Neuland Laboratories has made significant investments in capital expenditures, amounting to INR 254 crores in
Positive Financial Performance and Operational Efficiency
Despite a cash outflow, Neuland managed to limit free cash flows to a negative INR
NEULANDLAB Stock Challenges
NEULANDLAB Stock Challenges
6Decline in Gross Margins
The company reported a decrease in gross margins, with Q3 FY26 gross margin at 52.1%,
Deterioration in Working Capital
The company has experienced a deterioration in working capital, characterized by higher inventories and increased
NEULANDLAB Forecast
NEULANDLAB Forecasts
Price
Revenue
Earnings
NEULANDLAB Share Price Forecast
NEULANDLAB Share Price Forecast
2026
Current
₹17,345.00
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹17,345.00
Baseline
Forecast for Jun 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NEULANDLAB Company Revenue Forecast
NEULANDLAB Company Revenue Forecast
2026
Current
₹2.05
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.05
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹283.71
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹283.71
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NEULANDLAB
NEULANDLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NEULANDLAB Income Statement
NEULANDLAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 394.93 | 390.37 | 465.03 | 315.18 | 457.72 | 335.82 | 300.61 | 516.07 | 447.76 | 788.71 | ||||||||||
Operating & Other expenses | 271.56 | 278.09 | 316.24 | 248.62 | 311.43 | 277.29 | 258.26 | 358.73 | 362.58 | 468.92 | ||||||||||
EBITDA | 123.37 | 112.28 | 148.79 | 66.56 | 146.29 | 58.53 | 42.35 | 157.34 | 85.18 | 319.79 | ||||||||||
| Depreciation/Amortization | 15.14 | 16.46 | 16.28 | 16.07 | 16.30 | 16.89 | 20.19 | 22.54 | 23.92 | 25.09 | ||||||||||
| PBIT | 108.23 | 95.82 | 132.51 | 50.49 | 129.99 | 41.64 | 22.16 | 134.80 | 61.26 | 294.70 | ||||||||||
| Interest & Other Items | 3.74 | 3.61 | 2.67 | 1.06 | 2.22 | 2.35 | 4.58 | 5.37 | 6.79 | 7.21 | ||||||||||
| PBT | 104.49 | 92.21 | 129.84 | 49.43 | 127.77 | 39.29 | 17.58 | 129.43 | 54.47 | 287.49 | ||||||||||
| Taxes & Other Items | 23.09 | 24.64 | 31.97 | 16.58 | 26.18 | 11.49 | 3.67 | 32.58 | 13.90 | 74.82 | ||||||||||
| Net Income | 81.40 | 67.57 | 97.87 | 32.85 | 101.59 | 27.80 | 13.91 | 96.85 | 40.57 | 212.67 | ||||||||||
| EPS | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 | 75.49 | 31.62 | 165.76 |
NEULANDLAB Company Updates
FY 2026FY 2026
Investor Presentation
May 12PDF
Feb 9PDF
Nov 7PDF
Jul 31PDF
NEULANDLAB Stock Peers
NEULANDLAB Past Performance & Peer Comparison
NEULANDLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Neuland Laboratories Ltd | 61.14 | 14.59 | 0.20% |
| Sun Pharmaceutical Industries Ltd | 38.42 | 6.08 | 0.87% |
| Torrent Pharmaceuticals Ltd | 69.30 | 8.53 | 0.86% |
| Cipla Ltd | 28.15 | 3.16 | 0.96% |
NEULANDLAB Stock Price Comparison
Compare NEULANDLAB with any stock or ETFCompare NEULANDLAB with any stock or ETF
NEULANDLAB
NEULANDLAB Holdings
NEULANDLAB Shareholdings
NEULANDLAB Promoter Holdings Trend
NEULANDLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NEULANDLAB Institutional Holdings Trend
NEULANDLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding History
NEULANDLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in NEULANDLAB
Mutual Funds Invested in NEULANDLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Neuland Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9049% | Percentage of the fund’s portfolio invested in the stock 2.00% | Change in the portfolio weight of the stock over the last 3 months 0.33% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/95 (+35) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2404% | Percentage of the fund’s portfolio invested in the stock 1.64% | Change in the portfolio weight of the stock over the last 3 months 0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/114 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6976% | Percentage of the fund’s portfolio invested in the stock 2.41% | Change in the portfolio weight of the stock over the last 3 months 0.89% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/96 (+2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NEULANDLAB stock
smallcases containing NEULANDLAB stock
Looks like this stock is not in any smallcase yet.
NEULANDLAB Events
NEULANDLAB Events
NEULANDLAB Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NEULANDLAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.20%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.96 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NEULANDLAB Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NEULANDLAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.20%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.96 every year
NEULANDLAB Upcoming Dividends
NEULANDLAB Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 24, 2026
Final
Final | Div/Share: ₹34.00
Dividend/Share
₹34.00
Ex DateEx Date
Jul 24, 2026
NEULANDLAB Past Dividends
NEULANDLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2025
Final
Final | Div/Share: ₹12.00
Dividend/Share
₹12.00
Ex DateEx Date
Jul 18, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Final
Final | Div/Share: ₹14.00
Dividend/Share
₹14.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJun 29, 2021
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Jun 29, 2021
NEULANDLAB Stock News & Opinions
NEULANDLAB Stock News & Opinions
Articles & Videos
Corporate
Corporate
Neuland Laboratories board approves capacity additional at Unit 1The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)
1 month agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories board appoints directorThe board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories fixes record date for final dividendNeuland Laboratories has fixed 24 July 2026 as record date for purpose of determining the shareholders eligible to receive final dividend of Rs 34 per equity share of Re 10 for FY 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Neuland Laboratories consolidated net profit rises 664.72% in the March 2026 quarterNet profit of Neuland Laboratories rose 664.72% to Rs 212.67 crore in the quarter ended March 2026 as against Rs 27.81 crore during the previous quarter ended March 2025. Sales rose 136.40% to Rs 776.25 crore in the quarter ended March 2026 as against Rs 328.36 crore during the previous quarter ended March 2025. For the full year,net profit rose 39.94% to Rs 364.00 crore in the year ended March 2026 as against Rs 260.11 crore during the previous year ended March 2025. Sales rose 36.98% to Rs 2022.99 crore in the year ended March 2026 as against Rs 1476.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales776.25328.36 136 2022.991476.84 37 OPM %39.5915.56 -28.4021.89 - PBDT312.5856.19 456 580.72335.48 73 PBT287.4939.30 632 488.98269.93 81 NP212.6727.81 665 364.00260.11 40 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories to convene AGMNeuland Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 4 August 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Neuland Laboratories recommends final dividendNeuland Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, inter alia, have recommended the final dividend of Rs 34 per equity Share (i.e. 340%) , subject to the approval of the shareholders.
1 month agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories to conduct board meetingNeuland Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Neuland Laboratories consolidated net profit declines 60.06% in the December 2025 quarterNet profit of Neuland Laboratories declined 60.06% to Rs 40.57 crore in the quarter ended December 2025 as against Rs 101.59 crore during the previous quarter ended December 2024. Sales rose 10.47% to Rs 439.71 crore in the quarter ended December 2025 as against Rs 398.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales439.71398.03 10 OPM %17.5421.76 - PBDT78.4088.29 -11 PBT54.4871.98 -24 NP40.57101.59 -60 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories to conduct board meetingNeuland Laboratories will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Spotlight
Neuland Labs rises after Q2 PAT spurts 195% YoY to Rs 97 crOn a quarter-on-quarter (QoQ) basis, the company's net profit zoomed 596.76%, while revenue rose 75.67% in Q2 FY26. Profit before tax (PBT) soared 161.92% YoY and 636.71% QoQ to Rs 636.71 crore in Q2 FY26. During the quarter, EBITDA stood at Rs 156.9 crore, registering growth of 138.80% compared with Rs 65.7 crore posted in the same quarter last year. EBITDA margin improved 960 bps to 30.40% in Q2 FY26 as against 20.80% in Q2 FY25. Total expenses jumped 45.59% to Rs 386.64 crore in Q2 FY26, compared with Rs 265.75 crore in Q2 FY25. The cost of material consumed stood at Rs 227.64 crore (up 70.94% YoY), employee benefit expenses were at Rs 80.37 crore (up 28.43% YoY), finance cost stood at Rs 5.17 crore (up 387.74% YoY), while manufacturing expenses stood at Rs 45.96 crore (up 8.68% YoY) during the period under review. Sucheth Davuluri, vice-chairman and chief executive officer of the company, said, 'The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making, Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO and the generic APIs space. Customer interest in Neuland's capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but also a greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.' Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.47%, vs industry avg of 10.38%
Over the last 5 years, market share increased from 0.3% to 0.36%
Over the last 5 years, net income has grown at a yearly rate of 74.21%, vs industry avg of 19.71%